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Abstract
Introduction: Carboplatin and docetaxel are chemotherapy agents that are used to treat some
malignancies. This combination has not been documented to date to cause an inflammation of a
preexisting actinic keratosis. One previous report has described inflammation of AK lesions after the
use of docetaxel alone.
Case presentation: We report a case of a 54-year-old male with a history of untreated actinic
keratosis and lung cancer. He developed a rash on the sun exposed areas of skin after he received
carboplatin and docetaxel. Topical high-potency corticosteroid administration resulted in diminished
rash despite the ongoing chemotherapy regimen.
Conclusion: We present this case to emphasis this potential reaction in predisposed individuals
after using the combination of carboplatin and docetaxel, and to help physicians making the
appropriate decision whether to continue the chemotherapy or discontinued it.
Introduction
Actinic keratosis (AK) is a common skin lesion that occurs
in the elderly on sunlight exposed skin surfaces. Inflam-
mation of actinic keratosis secondary to chemotherapy
agents is a known phenomenon, most commonly
occurring with fluorouracil. To our knowledge, there has
been no report about the association between actinic
keratosis inflammation with the combination of carbo-
platin and docetaxel.
Case presentation
A 54-year-old Caucasian male presented with a one day
history of rash. The rash was on his upper trunk and
extensor surfaces of his arms. It was accompanied by a
burning sensation, but was otherwise non-tender to
palpation and non-pruritic. He had a history of COPD,
Hepatitis C, and previously unrecognized actinic keratosis.
He also had newly diagnosed adenocarcinoma of the lung
treated six days prior to presentation with a second cycle of
chemotherapy. The combination of carboplatin (798 mg)
and docetaxel (130 mg) was used for his regimen. Physical
exam revealed a chronically ill-appearing man with no
acute distress and intact oral mucosa. Skin examination
was notable for excessive dryness and multiple skin
lesions. The scalp had yellow, sharply bordered, scaly
lesions (Figure 1). The extensor surfaces of both arms
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(Figure 2), as well as the back of the neck, had numerous
non-tender nodules. The lesions were adherent, scaly,
erythematous, ranging from 5-10 mm in size, and circular
to ovoid in shape. This rash was consistent with an
inflamed actinic keratosis eruption secondary to his recent
chemotherapy. The rash improved with the treatment of
desonide cream 0.05%.
Discussion
Actinic keratosis is a common skin lesion that occurs in the
elderly on sunlight exposed skin surfaces. These lesions are
confined to the epidermis, but when they extend deeply
into the dermis, they called squamous cell carcinoma.
Numerous methods of AK treatment have been described
depending on the extent of the disease. They can include
cryotherapy, surgical removal, or topical drugs like
imiquimod and 5-fluorouracil (5-FU). 5-FU is successful
as a topical agent because it diffuses inside rapidly
replicating cells and kills them with minimal effect on
the normal cells. Toxic reaction and inflammation of the
lesions is known to occur during the early stages of
treatment. The inflammation can start within 1-2 weeks of
beginning treatment and it can include different phases
[1]. Different systemic chemotherapy agents and combi-
nation protocols are also known to produce an inflamma-
tion of the actinic keratosis via unclear mechanism.
Radiation recall reaction and susceptible cell with abnor-
mal DNA have been suggested to explain AK inflamma-
tion [2]. The most commonly described systemic
chemotherapy agent that can cause a flair of actinic
keratosis is 5-Fu [2]. Other cited agents include dactino-
mycin-dacarbazine-vincristine combination, doxorubicin-
cytarabine-thioguanine combination, sorafenib-tipifarnib
combination, capecitabine, doxorubicin, erlotinib, deox-
ycoformycin, fludarabine, and cisplatin [2-6]. Docetaxel,
one of the taxane agents, has been described in one report
to cause inflammation of actinic keratosis in two patients
[7]. No association between AK inflammation and the
alkylating agent carboplatin has been found in the
literature. To our knowledge, this is the first case report
describing an association between actinic keratosis inflam-
mation and the combination of carboplatin and docetaxel.
Our patient suffered from actinic keratosis inflammation
after his second chemotherapeutic treatment for lung
cancer using combination therapy. Certainly, it is known
that docetaxel alone may induce this response. We cannot
discern if the combination of these agents lead to a more
robust flair than if he had received solely docetaxel. It
should be investigated whether the sole use of carboplatin
also has a similar effect on AK.
Conclusion
Chemotherapy agents have been widely used to treat
malignancies, and many agents continue to be discovered
and added. Because of the time delay that occurs between
introducing new drugs and the documentation of their
new reactions, physicians, particularly oncologists and
dermatologists, should be aware of the potential cuta-
neous adverse effects of these agents. Inflammation of
preexisting and subclinical actinic keratosis is an effect of
particular interest. Screening for actinic keratosis prior to
initiating chemotherapy may be beneficial, particularly if
agents that are known to cause inflammation of AK are
being considered. This may provide an opportunity for
anticipatory guidance regarding a possible flair after
induction, and may prevent misdiagnosis of a drug
reaction with unnecessary skin biopsy or termination of
potentially life saving treatment.
Abbreviations
AK, actinic keratosis; 5-FU, 5-fluorouracil.
Figure 1. Patient scalp shows yellow, and scaly lesions
consistent with AK.
Figure 2. Patient right arm shows numerous scaly, and
erythematous nodules consistent with inflamed AK.
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